Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.

Hiroshi IshiguroShinji OhnoYutaka YamamotoShintaro TakaoNobuaki SatoTomomi FujisawaTakayuki KadoyaKatsumasa KuroiHiroko BandoYasufumi TeramuraHiroji IwataShiro TanakaMasakazu Toi

Published in: Breast cancer (Tokyo, Japan) (2019)

TOR might be a valid alternative to TAM in patients predicted to be poor TAM metabolizers.

Keyphrases

estrogen receptor
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
case report
randomized controlled trial
clinical trial
open label
clinical decision support
study protocol
breast cancer risk